ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly buys pain drug firm

by Michael McCoy
January 23, 2017 | APPEARED IN VOLUME 95, ISSUE 4

Eli Lilly & Co. will pay about $960 million to acquire CoLucid Pharmaceuticals, a publicly traded biotech firm that is developing lasmiditan, an oral 5-HT1F agonist for the treatment of migraine. Lasmiditan has completed the first of two Phase III clinical trials; data from one of them are expected later this year. If the data are positive, lasmiditan could be submitted for FDA approval in 2018. Lilly discovered lasmiditan and licensed it to CoLucid in 2005, at a time when Lilly was not focused on pain management. Now, the company is developing a pain management drug pipeline that includes galcanezumab for migraine and tanezumab, being developed with Pfizer for multiple indications. Lilly CEO David A. Ricks says lasmiditan could be the “the first significant innovation for the acute treatment of migraine in more than 20 years.”

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment